



Investor
Presentation

September 2023

FORWARD LOOKING STATEMENTS

This presentation has been prepared by Movano Inc. dba Movano Health (“we,” “us,” “our,” “Movano” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither this presentation, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation contains forward-looking statements concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; product development efforts and product releases; clinical trial and regulatory initiatives; commercial partner activities; as well as our strategies, positioning and expectations for future events or performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, and in our other reports filed with the Securities and Exchange Commission, including under the caption “Risk Factors.” Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

WE ARE BUILDING THE NEXT GENERATION OF WEARABLES




The Evie Ring is positioned to win in *both* consumer and enterprise




1

Evie Ring
Differentiation



2

First Mover Advantage
in B2B



3

Imminent D2C
Launch



4

Team, Future,
Upcoming Catalysts

COMPETITIVE ADVANTAGES



ENTERPRISE

NO EXISTING SOLUTION

- Pharma needs a medical-grade device for clinical trials and post-market surveillance
- Medical device companies need patient status for real-time optimization
- Payers need medical-grade Remote Patient Monitoring (RPM) capabilities
- Retailers are looking for health narrative

WOMEN-FOCUS

NO EXISTING SOLUTION

- Form factor and sizing designed for women
- Personalized insights derived from AI
- Gamify the process of getting healthier
- Menstrual health prioritized for all stages
- Mental health correlated with passively-collected ring data
- Medical grade technology

FITNESS & WELLNESS

INCUMBENT PRODUCTS ARE ONE-SIZE-FITS-ALL


- Serve fitness enthusiasts
- Focus on comms, staying connected
- Quantitatively track performance metrics
- Bring awareness to sleep duration and stages




evie

_____ uniquely positioned to satisfy these market needs _____

CURRENT ENGAGEMENTS ACROSS THE HEALTHCARE CONTINUUM



MOVANO HEALTH'S B2B OPPORTUNITY



HOW EVIE STACKS UP



	Steps & Activity	Sleep & Sleep Stages	Heart Rate (HRV, RHR)	SpO ₂	Skin Temp.	Menstrual Cycle	Mood Logging	Personal Insights	Form Factor/ Finishes	Price
evie	●	●	★	★	●	●	●	●	Gold, Silver, Rose Gold	\$269
fitbit	●	●	●	⊘*	●	●			Bands & Watches	\$99-\$299
WHOOP[®]	●	●	●	⊘*	●	●			Screenless Bands	\$20/month with 1-year commit
OURA	●	●	●	⊘*	●	●			Gold, Silver, Rose Gold, Black	\$299-\$549 & \$6/month sub

★ Potential for FDA clearance
● Full function
⊘ Limited function

*Fitbit, Whoop, and Oura devices make nighttime readings only

THE FIRST SMART RING TO FILE FOR FDA CLEARANCE ON SpO₂ & HR



Q4'22 HYPOXIA PIVOTAL TRIAL RESULTS

	SpO ₂ RMSE ¹	HR RMSE ²
FDA Benchmark	<3.5%	Within 2 bpm
Masimo - Radical-7	2.8%	1.5 bpm
Evie Ring	2.13%	~ 1 bpm

WAREABLE

WEARABLES

Movano Evie edges closer to launch as it hits the FDA

Movano looks for clearance for heart rate and SpO₂



News | Wearables | August 07, 2023

Movano Health Achieves Major Milestone with First FDA Filing for Evie Ring's Pulse Oximeter

The 510(k) application covers Evie Ring's pulse oximeter that includes heart rate and SpO₂ data, and is expected to make it one of the first consumer wearables that is also cleared for clinical use

FDA CLEARANCE SECURES COMPETITIVE Foothold IN ENTERPRISE MARKET



To Compete With Movano Health, Companies Would Have To:

1

Create Medical Device Infrastructure

- Implement a Quality Management System (QMS)
- Hire medical device team for Quality, Regulatory and Clinical (QRC)
- Train every employee on Standard Operating Procedures
- Manage ongoing initiatives to track product, complaints and Corrective and Preventative Actions (CAPAs)

2

Pursue FDA Clearance

- Establish clinical trials, generate all required documents

3

Build in FDA-Compliant Facility


- Set up production to comply with [FDA Good Manufacturing Practice](#)

Transitioning an existing wearables operation into a medical device company would be **cost prohibitive** and take **several years to execute**


MOVANO HEALTH AS A PLATFORM




Platform is designed to integrate partner and healthcare system data for future monetization



CONSUMER WEARABLE MARKET GROWING EXPONENTIALLY



EVIE PRODUCT LAUNCH HIGHLIGHTS



Imminent planned
launch




\$269 price point
with no monthly
subscription



Available in
US sizes 5-12

WOMEN ARE UNDERSERVED BY THE HEALTHCARE SYSTEM



While more connected to the healthcare system, most feel dismissed by providers¹



Heart disease is the #1 cause of death for women in the U.S.²



92% of women feel unprepared for menopause³

1,000+ WOMEN TOLD US WHAT THEY WANT:



Three-quarters are in the market, with a third currently using a watch or fitness tracker.

She wants to better understand her body, find balance, and improve sleep, but is not an elite athlete.

She does not want to pay a subscription and will pay for discreet health solutions.



IDI & SURVEY METHODOLOGY



Women between the ages of 35 and 75 in a series of 20 min interviews




Currently own or looking to purchase a wearable
Nationally representative sample who live in the U.S.


SNEAK PEAK: EVIE APP INSIGHTS EXPERIENCE




Passively collected
body data on sleep



Logged symptom +
cycle data



Educational insight based
on her experience




EVIE US MARKET TAM & COMPOSITION





27% of Women Surveyed Answered
"Extremely or Very Likely" to Buy¹


**~33M
WOMEN**



WE HAVE INSIGHT TO HEALTH ISSUES...


 Insomnia

 Depression


 Heart Disease


 Fertility

...AND HOW WE'LL TARGET THEM


 Influencers

 Celebrity Spokesperson

 Traditional Media

 Paid Advertisement

EVIE MARKETING REACH BY THE NUMBERS



MEDICAL ADVISORY BOARD

ESTABLISHES CREDIBILITY AND PROVIDES INSIGHTS



Dr. Ruth White
PhD, MPH, MSW, RSW



Dr. Mary-Claire Haver
MD, FACOG, CCMS



Dr. Andrea Matsumura
MD, MS, FACP



Dr. Fatima Rodriguez
MD, MPH

Specialty

Mental Health

OB/GYN (focus on menopause) & Nutrition

Physician / Sleep

Cardiology

Current Practice

Published Author, Speaker, and Diversity Expert

Founder & Author, The Galveston Diet Nutrition Program

Sleep Lab Director, Oregon Clinic

Associate Professor of Cardiovascular Medicine, Stanford Health Care

Education & Affiliations

Assoc. Professor, USC
Tenured Professor, Seattle University

Clinical Instructor, UT Health

Fellowship, Oregon Health & Science Univ.
MD, San Antonio Med. School

MD, Harvard Medical School
MPH, Harvard School of Public Health

OUR SEASONED TEAM HAS DIVERSIFIED EXPERIENCE AND VISION TO SUCCEED



**JOHN MASTROTOTARO,
PHD
CEO**

- Former Medtronic exec.
- 30+ years medical device industry



**MICHAEL LEABMAN
FOUNDER & CTO**

- CTO of 4 wireless startups
- 20+ years smart antenna
- 200+ issued patents



**J. COGAN
CFO**

- 24 years Wall Street experience, investor & analyst



**TYLA BUCHER
CMO**

- 20+ years launching global consumer products & brand campaigns



**KIM TOMPKINS
QRC**

- 30+ years FDA Class II/III devices, digital health & cardiovascular



**STACY SALVI, J.D.
STRATEGY**

- Former Head of Strategic Partnerships for Fitbit at Google



**ED LANDAU
ENGINEERING**

- 25+ years in product development in medical & consumer tech electronics



**MICHAEL SOULE
BIZ DEV**

- 20+ years managing sales & biz dev for consumer and medical products



**JIM VOYDAT
OPERATIONS**

- 30+ years manufacturing operations & global supply chain management



LEADERSHIP

Our patented System-on-a-Chip was built from the ground up

After four years in development, the smallest ever custom RF-enabled IC designed for blood pressure and glucose monitoring is now functional, providing:


Greater accuracy

Flexibility in form factor

Cost-effective solutions

THE POWER OF 4 CHIPS IN 1

Meet Movano Health's custom
mmWave integrated sensor



Actual chip size: 4mm x 6.7mm

Movano Health patent summary

US: 23 Issued, 33 Pending

Foreign: 1 Issued (China),
4 Pending (1 China/3 Europe)

KEY US PATENTS FALL INTO FOUR CATEGORIES

RF IC Architecture (3) Issued

Covers RF IC design, including multi-band mixing and conductor loss mitigation that is critical at high frequencies.

Key Issued Patents:

- Systems for multi-band radar-based sensing (US 11,298,037)
- Methods for multi-band radar-based sensing (US 10,874,314)

Ring (3) Pending

Covers various aspects of the current Evie Ring and charger design, including the 2-piece open-ended construction, production efficiencies, and control efficiencies.

Pending Patents:

- Finger wearable health monitoring device
- Finger wearable devices and methods for producing finger wearable devices
- Ring charging case



RF-Based Health Monitoring (15) Issued (25) Pending

Covers signal processing techniques for generating high resolution pulse wave signal to determine HR, BP, BG level.

Key Issued Patents:

- Systems for RF-based health monitoring utilizing amplitude and phase data (US 11,445,929)
- Methods and systems for monitoring BP using stepped frequency radar with spectral agility (US 11,360,188)
- Systems for health monitoring using radio waves that include mixing signals at different frequencies (US 11,583,199)
- Methods for radio wave-based health monitoring that utilize data derived from amplitude and/or phase data (US 11,576,586)-


Machine Learning Applications (2) Issued (8) Pending

Techniques for generating training data and training ML models for health monitoring, and techniques for utilizing ML models for health monitoring, including blood pressure and blood glucose.

Key Issued Patents:

- Methods for training a model for use in RF-based health monitoring (US 11,464,419)
- Methods for training a model for use in radio waved based blood pressure monitoring (US 11,596,321)


PRODUCT ENHANCEMENT OPPORTUNITIES



Systolic


Blood Pressure Measurements

Robust Internal Technical Expertise and Patented RF Technology Allows for Continued Product Development



Diastolic

Glucose Monitoring



CORPORATE SNAPSHOT (NASDAQ: MOVE)



DOLLARS RAISED
\$102M*

YEAR FOUNDED
2018

IP PORTFOLIO:

US 23 patents issued, 33 pending
OUS 1 patent issued, 4 pending

LTM CASH BURN 6/30/23
\$27M

NUMBER OF FTES
37

CASH AT 6/30/23
\$14.5M

CORPORATE ENTITIES:
Movano Inc. dba
Movano Health
Movano Ireland



* In August 2022, the Company entered into an At the Market Issuance Agreement with B. Riley Securities, Inc. Pursuant to the terms of the Issuance Agreement, the Company may sell from time to time through the Sales Agent shares of the Company's common stock having an aggregate offering price of up to \$50M.

NASDAQ: MOVE

+1 (415) 651-3172

6800 Koll Center Pkwy.
Pleasanton, CA 94566

www.movanohealth.com
www.eviering.com

